Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 485-490     DOI: 10.1007/s11684-009-0089-3
Research articles |
Effect of pEGFP-survivin on GBC-SD cell growth and chemotherapy sensitivity
Hanbin SHEN MD1,Bin ZHANG MBA1,Song ZHAO BM1,Qichang ZHENG MD2,Jianping GONG MD3,Xiaotang CAI BM4,
1.Department of General Surgery, The Fifth Hospital of Wuhan, Wuhan 430050, China; 2.Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 3.Department of Intestines and Stomach Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 4.Department of Surgery, The 477th Hospital of People''s Liberation Army, China;
Download: PDF(215 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This paper is aimed to investigate the effect of survivin shRNA on chemotherapy resistance in human gallbladder carcinoma GBC-SD cells. The viability of human gallbladder carcinoma GBC-SD, GBC-SD/enhanced green fluorescent protein (EGFP), and GBC-SD/survivin cells was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and mRNA and protein of survivin were tested by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot. After the cells were treated with cisplatin (DDP) (3.0 μg/mL) for the same time, cell survival rate and IC50 was detected with MTT, cell apoptosis was detected with fluorescence-activated cell sorting (FACS), and the nuclear alteration was observed by TdT-mediated deoxyuridine triphosphate nick end labeling (TUNEL). In addition, caspase-3 activity was detected by using colorimetric method. Cell viability was decreased significantly in GBC-SD/survivin cells, and survivin expression was decreased significantly (mRNA and protein of survivin were decreased by 74.7% and 71.5%, respectively). After treatment with DDP, cell survival rate and IC50 was decreased significantly (2.03±0.24 μg/mL) in GBC-SD/survivin cells, while apoptotic rate (84.3%) was elevated significantly as compared with the other two groups. There were brown apoptotic nuclei in all the cells. Caspase-3 activity in all the cells was increased at first and then decreased, but the caspase-3 activity in GBC-SD/survivin cells was significantly higher than the other two groups. The survivin shRNA could down-regulate the expression of survivin in GBC-SD cells significantly and improve the sensibility to chemotherapy.
Keywords survivin      shRNA      chemotherapy      sensibility      GBC-SD      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0089-3     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/485
Tamm I, Wang Y, Sausville E, Scudiero D A, Vigna N, Oltersdorf T, Reed J C. IAP-familyprotein survivin inhibits caspase activity and apoptosis induced byFas (CD95), Bax, caspase, and anticancer drugs. Cancer Res, 1998, 58(23): 5315–5320
Altieri D C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 2002, 3(1): 46–53

doi: 10.1038/nrc968
Olie R A, Simoes-Wust A P, Baumann B, Leech S H, Fabbro D, Stahel R A, Zangemeister-Wittke U. A novel antisenseoligonucleotide targeting survivin expression induce apoptosis sensitizeslung cancer cells to chemotherapy. CancerRes, 2000, 60(11): 2805–2809
Pennati M, Colella G, Folini M, Citti L, Daidone M G, Zaffaroni N. Ribozyme-mediatedattenuation of survivin expression sensitizes human melanoma cellsto cisplatin-induced apoptosis. J ClinInvest, 2002, 109(2): 285–286
Wu L, Wang Y, Tian D. Knockdown of survivin expression by siRNA induces apoptosisof hepatocellular carcinoma cells. J HuazhongUniv Sci Technol Med Sci, 2007, 27(4): 403–406

doi: 10.1007/s11596-007-0413-6
Wang Y, Zhu Z, Zeng F, Wang L, Wu Y, Xia W, Xing S. Expression and prognostic significanceof survivin in the progression of bladder transitional cell cancer. J Huazhong Univ Sci Technol Med Sci, 2007, 27(4): 444–447

doi: 10.1007/s11596-007-0424-3
Ferreira C G, Epping M, Kruyt F A, Giaccone G. Apoptosis:target of cancer therapy. Clin Cancer Res, 2002, 8(7): 2024–2034
Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancerand lymphoma. Nat Med, 1997, 3(8): 917–921

doi: 10.1038/nm0897-917
Shin S, Sung B J, Cho Y S, Kim H J, Ha N C, Hwang J I, Chung C W, Jung Y K, Oh B H. An anti-apoptoticprotein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 2001, 40(4): 1117–1123

doi: 10.1021/bi001603q
Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomasto anti-cancer treatment. Ann N Y AcadSci, 2000, 926: 204–216
Sarela A I, Verbeke C S, Ramsdale J, Davies C L, Markham A F, Guillou P J. Expression of survivin, a novel inhibitor of apoptosisand cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer, 2002, 86(6): 886–892

doi: 10.1038/sj.bjc.6600133
Tenllado F, Llave C, Díaz-Ruíz J R. RNA interference as a newbiotechnological tool for the control of virus diseases in plants. Virus Res, 2004, 102(1): 85–96

doi: 10.1016/j.virusres.2004.01.019
Tijsterman M, Plasterk R H. Dicers at RISC; the mechanismof RNAi. Cell, 2004, 117(1): 1–3

doi: 10.1016/S0092-8674(04)00293-4
Kwon M, Scholey J M. Spindle mechanics and dynamicsduring mitosis in Drosophila. Trends Cell Biol, 2004, 14(4): 194–205

doi: 10.1016/j.tcb.2004.03.003
Pham J W, Pellino J L, Lee Y S, Carthew R W, Sontheimer E J. A Dicer-2-dependent 80s complexcleaves targeted mRNAs during RNAi in Drosophila. Cell, 2004, 117(1): 83–94

doi: 10.1016/S0092-8674(04)00258-2
Cheng C P, Pogany J, Nagy P D. Mechanism of DI RNA formation in tombusviruses: dissectingthe requirement for primer extension by the tombusvirus RNA dependentRNA polymerase in vitro. Virology, 2002, 304(2): 460–473

doi: 10.1006/viro.2002.1713
Schwarz D S, Hutvagner G, Du T, Xu Z, Aronin N, Zamore P D. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115(2): 199–208

doi: 10.1016/S0092-8674(03)00759-1
Arenz C, Schepers U. RNA interference: from anancient mechanism to a state of the art therapeutic application? Naturwissenschaften, 2003, 90(8): 345–359

doi: 10.1007/s00114-003-0441-4
Raff M. Cellsuicide for beginners. Nature, 1998, 396(6707): 119–122

doi: 10.1038/24055
Chen R H, Chang T Y. Involvement of caspase familyprotease in transforming growth factor-beta induced apoptosis. Cell Growth Differ, 1997, 8(7): 82–87
Fujikawa K, Shiraki K, Sugimoto K, Ito T, Yamanaka T, Takase K, Nakano T. Reduced expression of ICE/caspase-1and CPP32/caspase-3 in human hepatocellular carcinoma. Anticancer Res, 2000, 20(3B): 1927–1932
Endo K, Ashida K, Miyake N, Terada T. E-cadheringene mutations human intrahepatic holangiocarcinoma. J Pathol, 2001, 193(3): 310–317

doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K
Joo Y E, Park C S, Kim H S, Choi S K, Rew J S, Kim S J. Prognostic significance of E-cadherin/catenin complex expressionin gastric cancer. J Korean Med Sci, 2000, 15(6): 655–666
[1] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[2] Cuihong ZHENG, Yunxia WU, Guangying HUANG, Wei WANG. Gene silencing efficiency of shRNA expression vectors targeting Cx43 in vitro[J]. Front Med Chin, 2009, 3(2): 130-135.
[3] YU Xiaobing, DAI Hong, LU Yingyi, LONG Li. Photodynamic therapy combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization[J]. Front. Med., 2007, 1(4): 405-409.
[4] XIONG Ying, GUO Wen, LI Ting, LI Ke. Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells[J]. Front. Med., 2007, 1(3): 304-307.
[5] RAO Rongsheng, CHEN Wenxue, ZHOU Xinwen, ZHOU Zheng, LI Xiaojun, ZENG Zhiping. Clinical outcomes of ATP-tumor chemosensitivity assay directed chemotherapy in hepatocellular carcinoma[J]. Front. Med., 2007, 1(2): 157-160.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed